CervoMed is trading 5.73% higher at $2.40 on October 14, 2026, with no company-specific announcement explaining the move identified in available coverage.
- The latest company news was an October 12 update on Phase 2a biomarker results.
- Healthcare-sector strength may be a supporting factor after UnitedHealth beat third-quarter estimates and raised its 2026 profit outlook, though this does not establish a direct cause for CervoMed’s gain.